In this paper, we propose a novel anomaly detection method for data centers based on a combination of graphstructure and abnormal attention mechanism. The method leverages the sensor monitoring data from targetpower s...In this paper, we propose a novel anomaly detection method for data centers based on a combination of graphstructure and abnormal attention mechanism. The method leverages the sensor monitoring data from targetpower substations to construct multidimensional time series. These time series are subsequently transformed intograph structures, and corresponding adjacency matrices are obtained. By incorporating the adjacency matricesand additional weights associated with the graph structure, an aggregation matrix is derived. The aggregationmatrix is then fed into a pre-trained graph convolutional neural network (GCN) to extract graph structure features.Moreover, both themultidimensional time series segments and the graph structure features are inputted into a pretrainedanomaly detectionmodel, resulting in corresponding anomaly detection results that help identify abnormaldata. The anomaly detection model consists of a multi-level encoder-decoder module, wherein each level includesa transformer encoder and decoder based on correlation differences. The attention module in the encoding layeradopts an abnormal attention module with a dual-branch structure. Experimental results demonstrate that ourproposed method significantly improves the accuracy and stability of anomaly detection.展开更多
Objective:This study aimed to evaluate the safety,efficacy,and feasibility of the rituximab,fotemustine,pemetrexed,and dexamethasone(R-FPD)regimen followed by whole-brain radiotherapy(WBRT)for patients with primary ce...Objective:This study aimed to evaluate the safety,efficacy,and feasibility of the rituximab,fotemustine,pemetrexed,and dexamethasone(R-FPD)regimen followed by whole-brain radiotherapy(WBRT)for patients with primary central nervous system lymphoma(PCNSL).Methods:A prospective,single-center phase II clinical trial was conducted.Patients with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were studied.The R-FPD regimen consisted of rituximab(375 mg/m2 i.v.on D0),fotemustine(100 mg/m2 i.v.on D1),pemetrexed(600 mg/m2 i.v.on D1),and dexamethasone(40 mg i.v.on D1-5).Patients 60 years or younger who showed a complete response(CR)were treated with 23.4 Gy of WBRT after the end of chemotherapy;those older than 60 years with CR were treated with a wait-and-see approach;and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy+local tumor field irradiation up to 45 Gy,regardless of age.Results:A total of 30 patients were included.After 2 cycles,the objective response rate(ORR)was 96.5%(28/29,1 CR,27 PR,0 SD,and 1 PD).After 4 cycles,the ORR was 73.1%(19/26,11 CR,8 PR,4 SD,and 3 PD).After WBRT,the ORR was 90.9%(10/11,7 CR,3 PR,and 1 SD).The grade III and IV toxicity responses were mainly leukopenia(20.0%),thrombocytopenia(23.3%),and anemia(10.0%).Conclusions:Fotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes,providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.展开更多
基金the Science and Technology Project of China Southern Power Grid Company,Ltd.(031200KK52200003)the National Natural Science Foundation of China(Nos.62371253,52278119).
文摘In this paper, we propose a novel anomaly detection method for data centers based on a combination of graphstructure and abnormal attention mechanism. The method leverages the sensor monitoring data from targetpower substations to construct multidimensional time series. These time series are subsequently transformed intograph structures, and corresponding adjacency matrices are obtained. By incorporating the adjacency matricesand additional weights associated with the graph structure, an aggregation matrix is derived. The aggregationmatrix is then fed into a pre-trained graph convolutional neural network (GCN) to extract graph structure features.Moreover, both themultidimensional time series segments and the graph structure features are inputted into a pretrainedanomaly detectionmodel, resulting in corresponding anomaly detection results that help identify abnormaldata. The anomaly detection model consists of a multi-level encoder-decoder module, wherein each level includesa transformer encoder and decoder based on correlation differences. The attention module in the encoding layeradopts an abnormal attention module with a dual-branch structure. Experimental results demonstrate that ourproposed method significantly improves the accuracy and stability of anomaly detection.
基金supported by grants from the National Natural Science Foundation of China(Grant No.81970184),The National Science and Technology Major Project of China(Grant No.2020ZX09201-009)Henan Medical Science and Technology Tacking Program(Joint Project)(Grant No.LHGJ20190021)。
文摘Objective:This study aimed to evaluate the safety,efficacy,and feasibility of the rituximab,fotemustine,pemetrexed,and dexamethasone(R-FPD)regimen followed by whole-brain radiotherapy(WBRT)for patients with primary central nervous system lymphoma(PCNSL).Methods:A prospective,single-center phase II clinical trial was conducted.Patients with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were studied.The R-FPD regimen consisted of rituximab(375 mg/m2 i.v.on D0),fotemustine(100 mg/m2 i.v.on D1),pemetrexed(600 mg/m2 i.v.on D1),and dexamethasone(40 mg i.v.on D1-5).Patients 60 years or younger who showed a complete response(CR)were treated with 23.4 Gy of WBRT after the end of chemotherapy;those older than 60 years with CR were treated with a wait-and-see approach;and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy+local tumor field irradiation up to 45 Gy,regardless of age.Results:A total of 30 patients were included.After 2 cycles,the objective response rate(ORR)was 96.5%(28/29,1 CR,27 PR,0 SD,and 1 PD).After 4 cycles,the ORR was 73.1%(19/26,11 CR,8 PR,4 SD,and 3 PD).After WBRT,the ORR was 90.9%(10/11,7 CR,3 PR,and 1 SD).The grade III and IV toxicity responses were mainly leukopenia(20.0%),thrombocytopenia(23.3%),and anemia(10.0%).Conclusions:Fotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes,providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.